Trained and supervised by internationally recognized experts, we have acquired skills in a variety of inflammatory disease models at QPS. Such 
models can be applied to study immune responses, biomarkers, and the pathophysiology following specific triggers and for proof of concept studies with (targeted) interventions. Disease models also offer the advantage of (non-invasive) biomarker samplings, thus enabling us to link pharmacokinetics to physiological and immunological responses and clinical outcomes.
Apart from our extensive experience with the inhalational and nasal allergen challenge model and virus inoculation in respiratory studies, we are expanding our capabilities with the ‘neutrophilic’ lipopolysaccharide (LPS) model. Presently, we are conducting a study in healthy volunteers using intravenous purified (GMP) lipopolysaccharide (LPS) under close monitoring by our expert team. Joining forces with Professor Tony Absalom (anesthesiologist at the University Medical Center Groningen), we have thus successfully induced this ‘’neutrophilic status’’ in a number of participants in an interventional study with a new drug entity.
With the implementation of this inflammatory model in combination with our biomarker sampling and quantification capabilities, QPS has reached another milestone towards all-round services for drug development.
Khalid Abd-Elaziz, MBBS, MD, clinical pharmacologist, Principal Investigator and Associate Medical Director
Professor Zuzana Diamant, MD PhD, pulmonologist-clinical pharmacologist, Principal Investigator and Scientific & Executive Medical Director Respiratory & Allergy
For information on Respiratory and Allergy Capabilities, you may also contact Zuzana Diamant, MD PhD, pulmonologist-clinical pharmacologist, Principal Investigator and Scientific and Executive Medical Director Respiratory & Allergy at QPS Netherlands: zuzana.diamant@www.qps.com and z.diamant@gems.demon.nl.
